Adocia SA (EPA:ADOC)

Market Cap	81.80M
Revenue (ttm)	12.12M
Net Income (ttm)	-9.32M
Shares Out	18.08M
EPS (ttm)	-1.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	306,486
Average Volume	218,138
Open	4.470
Previous Close	4.525
Day's Range	4.060 - 4.675
52-Week Range	2.860 - 10.960
Beta	0.47
RSI	52.76
Earnings Date	Apr 17, 2025

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and ra...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 78
• Stock Exchange: Euronext Paris
• Ticker Symbol: ADOC

Financial Performance

In 2024, Adocia's revenue was 12.12 million, an increase of 100.43% compared to the previous year's 6.05 million. Losses were -9.32 million, -55.95% less than in 2023.